For QA analysis for images from many different sources, Rad Image provides RIT113, a single QA package that can provides solutions for several imaging options.

RIT 113 is a Windows-based software with interactive, real time graphical user interface. It is designed for cancer centers that use a mix of conventional therapy, advanced therapies, IMRT, IGRT and RapidArc digital and film images.

Oncology Data Systems develops MUCheck a monitor unit/dose verification software for use in radiation therapy clinics.

Designed to validate dose and monitor unit calculations performed by primary radiation treatment planning software, MUCheck is a Windows-based, IBM compatible program that operates independently of any treatment planning system. MUCheck’s list of features enables medical professionals in the therapy department to perform calculations reportedly quickly and with ease of use.

Intrabeam is a miniature radiation source that delivers high-dose, yet is a low energy X-ray used for breast cancer therapy, neurosurgery and other radiation therapies developed by Carl Zeiss Meditec.

The Intrabeam System can be used to treat early stage breast cancer. The radiation dose is administrated to the tumor bed in the operating room, following lumpectomy.

CDR Systems offers Head and Neck Treatment System, a head, neck and shoulder immobilization system designed for unobstructed 360-degree treatment of the head and neck. An indexable overlay board is also available as well as a treatment couch extension that can be adapted to lock onto any brand and model of treatment couch.

C-RAD Sentinel is a new system for surface contour localization and monitoring of the patient in the radiotherapy treatment process.

The C-RAD Sentinel basic platform is based on advanced laser technology with multipurpose software modules covering different tasks in the treatment procedure. The different software modules are integrated with other systems in the clinic.

August 1, 2008 – The Centers for Medicare & Medicaid Services (CMS) yesterday issued a final ruling for three new hospital errors or conditions it will no longer pay for, including: surgical site infections following certain elective procedures, including certain orthopedic surgeries, and bariatric surgery for obesity; certain manifestations of poor control of blood sugar levels; and deep vein thrombosis or pulmonary embolism following total knee replacement and hip replacement procedures.

August 1, 2008 – BSD Medical Corp. said its BSD-2000/3D/MR cancer treatment system has been adapted to treat children with cancer.

To accommodate the treatment of children, BSD has developed treatment applications specifically sized for small and medium-sized children and that are capable of delivering pediatric cancer therapy during simultaneous magnetic resonance imaging (MRI) during the treatment process.

August 1, 2008 - Healthcare professionals need an authoritative resource on the Internet designed to quickly provide answers to urgent treatment questions, so Epocrates partnered with BMJ Group, publisher of the British Medical Journal, to create a new online product that delivers practical and up-to-date disease diagnosis and treatment guidelines.

July 31, 2008 - Bristol-Myers Squibb Co. today offered $4.5 billion in cash for its cancer drug partner, ImClone Systems, a biotechnology company that makes ERBITUX (Cetuximab), a drug used in combination with radiation therapy for the treatment of advanced head and neck cancers.

ImClone’s board has not commented on the proposal, which offers its stockholders $60 per share, a 30 percent premium to New York-based ImClone's closing price of $46.44 Wednesday. New York-based Bristol-Myers already owns about 17 percent of ImClone.

Xoft Inc. recently received FDA clearance for applicators to be used with the Axxent Electronic Brachytherapy System for the treatment of endometrial cancer.

Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now